Neovascular Age-Related Macular Degeneration Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Neovascular Age-Related Macular Degeneration remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 272 matched trial records and 921 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600128124 | Aflibercept | Phase 4; Not yet recruiting | The Second Affiliated Hospital Zhejiang University | China | The percentage of decrease in the number of HRF from baseline to week 12; The percentage of stable in the number of HRF from baseline to week 12 | 2027-12-31 |
| NCT07695207 | Intervention not normalized | Phase 3; Recruiting | Sangmyung University | South Korea | Best corrected visual acuity (BCVA) at Month 12 (Month 12) | 2027-12-01 |
| ChiCTR2600127294 | Intervention not normalized | Phase 4; Recruiting | Sponsor not listed | China | Mean change in central subfield thickness from baseline to month 12 (baseline and month 12; change from baseline to month 12); Mean change in maximum pigment epithelial detachment height from baseline to month 12 (baseline and month 12; change from baseline to month 12) | 2028-06-30 |
| NCT07640997 | Aflibercept | Not Applicable; Recruiting | Peking University People's Hospital | China | The change of best corrected visual acuity (BCVA) from baseline to 12 months（BCVA will be examined under real-world conditions and converted into ETDRS letters. ） (Baseline to Month 12) | 2027-08-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT (Phase 3): the indexed record reports BCVA(Mean) = 63.0 letters (Standard Deviation, 13.5); BCVA(Mean) = 66.2 letters (Standard Deviation, 12.6); -.
- Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results (Phase 1): the indexed record reports Supplemental anti-VEGF injections(1 year) = 91.7 %.
- A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe (Phase 3): the indexed record reports Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS = 35 injections; -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Aflibercept (Approved; PGF x VEGF-A). Company & Deal Intelligence records identify sponsor context for The Second Affiliated Hospital Zhejiang University, Sangmyung University, Peking University People's Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Neovascular Age-Related Macular Degeneration has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
